Zensun is developing a novel treatment for Chronic Heart Failure (CHF), a syndrome where the heart is unable to supply sufficient blood flow to meet the needs of the body. It is estimated that the prevalence of CHF is ~5.3 million people in the United States with 550,000 new cases reported each year.
Neucardin™ is a small peptide that binds receptors on the outside of cardiac muscle cells. Once bound many key molecules that are involved in cardiac muscle cell structure and contractile function restoration are activated in the cell.
Neucardin™ has been given to ~1000 subjects with CHF and over 1500 people have been involved in 16 clinical trials in China, Australia and the United States.
Although the primary targeted indication for Neucardin™ is CHF with impaired systolic function, because of its ability to improve cardiac muscle structure and function, Neucardin™ also holds potential to improve CHF associated with impaired diastolic function, increase heart function in the acute setting as well as treat ischemic reperfusion injury.